What is the therapeutic effect of serputinib/serpatinib?

Selpercatinib is a targeted drug that has attracted much attention in the field of cancer treatment in recent years, especially in targeting tumors caused by RET gene abnormalities. It has shown significant efficacy. RET基因突变与多种癌症类型的发生密切相关，包括非小细胞肺癌（NSCLC）和甲状腺癌等。 Research results in recent years have shown that the use of the drug Seputinib can effectively shrink tumors, bringing new hope to the treatment of patients.

In a study of patients with RET gene abnormalities, seputinib showed its effectiveness in shrinking tumors without being compared to other drugs or a placebo. Especially among patients with non-small cell lung cancer who had received platinum-based chemotherapy, 64% of patients treated with seputinib had their tumors reduced in size. Specifically, 67 of 105 patients achieved the goal of tumor shrinkage. Among those patients who had not received any previous treatment, 84% had a complete or partial response to treatment with seputinib, demonstrating the drug's great potential in treatment-naïve patients.

除了肺癌外，塞普替尼还被用于其他类型的实体瘤患者的治疗。研究中包括52名患有不同类型实体瘤的成年人，主要是胰腺癌和结肠癌。这些患者大多数都曾经接受过其他治疗，但没有接受过RET抑制剂的治疗。结果表明，大约44%的患者在平均持续治疗37个月后，获得了完全或部分的癌症反应。这一结果不仅证明了塞普替尼在不同类型癌症患者中的有效性，也为后续的治疗策略提供了依据。

在甲状腺癌的研究中，塞普替尼同样展现出了令人瞩目的效果。 Of 19 adult thyroid cancer patients who had been treated with sorafenib or lenvatinib, 79% experienced a reduction in tumor size with seputinib. Among the other 24 thyroid cancer patients who had not received other treatments (except radioactive iodine), about 96% of the patients also achieved tumor shrinkage. These data suggest that seputinib is highly effective in treating thyroid cancer, especially in patients who have not responded well to other therapies.

在青少年患者的研究中，塞普替尼同样显示出积极的前景。 A study of patients aged 12 to 21 who had received other treatments or were unable to receive effective treatments showed that 60% of the patients saw their cancer shrink. This provides a scientific basis for the use of seputinib in adolescent patients because the distribution and clearance mechanisms of the drug in children and adolescents are similar to those in adults.

Results in patients with advanced medullary thyroid cancer are also encouraging. In a group of adults and adolescent patients over the age of 15, 73.5% of patients who had previously been treated with capozantinib or vandetinib experienced tumor shrinkage, while 81% of patients who had not been treated with either drug also experienced tumor shrinkage. This result demonstrates the effectiveness of seputinib in different treatment settings, especially in patients with complex conditions, showing good therapeutic prospects.

Reference:https://en.wikipedia.org/wiki/Selpercatinib